已发表论文

血清 IL-22、IL-23 和 IL-17 水平对肺癌相关特发性肺纤维化的诊断价值

 

Authors Zhang Q, Tong L, Wang B, Wang T, Ma H 

Received 17 November 2021

Accepted for publication 28 March 2022

Published 19 April 2022 Volume 2022:18 Pages 429—437

DOI https://doi.org/10.2147/TCRM.S349185

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr De-Yun Wang

Background: Correlations between idiopathic pulmonary fibrosis (IPF) and lung cancer have been discussed in many previous studies. In the present work, we evaluated the potential diagnostic value of serum levels of Th17 cell-related cytokines for the detection of lung cancer-associated IPF.
Methods: Fifty-six patients who had been diagnosed with lung cancer-associated IPF were enrolled, and 59 patients with lung cancer but without IPF were also enrolled, and 60 healthy volunteers were served as the control group. The expression of IL-22, IL-23, and IL-17 was evaluated by enzyme-linked immunosorbent assay (ELISA) kits.
Results: We observed that IL-22, IL-23 as well as IL-17 were significantly increased in the serum of lung cancer patients associated IPF; moreover, the results of ROC curve showed that the expression of IL-22, IL-23 and IL-17 can distinguish the lung cancer patients with lung cancer-associated IPF group; finally, the expression of IL-22, IL-23 and IL-17 was positively correlated with the degree of differentiation and metathesis of the tumor.
Conclusion: In conclusion, we first reported that IL-22, IL-23 and IL-17 were elevated in the serum of patients with lung cancer-associated IPF, and our data may provide novel evidence for the prevention and treatment of lung cancer-associated IPF.
Keywords: idiopathic pulmonary fibrosis, diagnosis, IL-22, IL-23, IL-17, lung cancer